Hemorrhoids treatment market seen nearly doubling by 2035

Market Research Future projects the global hemorrhoids treatment market will grow from $1.44 billion in 2024 to $2.99 billion by 2035, driven by rising prevalence, more awareness and wider use of minimally invasive procedures. North America leads the market now, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - The hemorrhoids treatment market is forecast to nearly double by 2035, pointing to more demand for drugs, procedures and devices. - Growth could benefit companies focused on minimally invasive care, telehealth and home-use treatment options. - Wider awareness may push more patients to seek care earlier instead of delaying treatment because of embarrassment.

What happened: - Market Research Future projected the global hemorrhoids treatment market will rise from $1,441.59 million in 2024 to $2,994.6 million by 2035. - The report said the market is expected to grow at a 6.83% compound annual growth rate from 2025 to 2035. - The report was shared Aug. 26, 2026. - The company offered a free sample and customization request for the report.

The details: - Rising hemorrhoid prevalence is a major growth driver, tied to sedentary lifestyles, unhealthy diets and low fiber intake. - Hemorrhoids affect most people under 50, according to the report. - Technological advances are improving treatment efficacy, patient comfort and recovery times. - Minimally invasive options such as rubber band ligation and infrared coagulation are gaining ground over traditional surgery. - The report also cited laser therapy, sclerotherapy, novel pharmacological agents and combination therapies as areas of momentum. - Non-surgical and pharmacological treatments dominate the market. - Topical treatments hold the largest share at 44% because they are easy to use and provide immediate effects. - Surgical procedures include hemorrhoidectomy, stapled hemorrhoidopexy and laser surgery, and remain important for severe cases. - Minimally invasive procedures are the fastest-growing treatment segment. - Moderate cases make up the largest severity segment at 48%. - Severe cases are the fastest-growing severity segment. - Adults represent the largest patient group at 58%. - The elderly are the fastest-growing patient group. - Pharmacies remain the dominant distribution channel. - Online retail is the fastest-growing channel as younger consumers look for convenience and discretion. - North America holds the largest regional share, supported by advanced healthcare infrastructure, high awareness and easier access to innovative therapies. - The United States is a key contributor because of a high incidence rate and rising demand for minimally invasive treatment options. - Europe is the second-largest market, with Germany, the UK and France as major contributors. - Asia-Pacific is expected to be the fastest-growing region, led by India and China.

Between the lines: - The report points to a market shift away from invasive surgery and toward lower-pain, faster-recovery treatments. - Public education campaigns are important because stigma still keeps many patients from seeking care. - The World Gastroenterology Organization's World Digestive Health Day campaign is being used to raise awareness of gastrointestinal disorders, including hemorrhoids. - Competition is already active, with product launches, partnerships and acquisitions shaping strategy. - Companies named in the report include Johnson & Johnson, Medtronic, Pfizer, Abbott Laboratories, Boston Scientific, Bayer, GlaxoSmithKline, Cook Medical, B. Braun Melsungen, CONMED, Teva Pharmaceutical Industries and Takeda.

What's next: - Market Research Future expects continued growth through 2035 as awareness rises and treatment options expand. - New opportunities are likely in portable home-use devices, telehealth consultations and follow-up care. - Partnerships with healthcare providers could drive more integrated treatment solutions. - Asia-Pacific may narrow the gap with mature markets if healthcare access and pharmaceutical infrastructure keep improving.

The bottom line: - Hemorrhoids treatment is moving from a niche clinical category to a broader, more accessible care market, with minimally invasive therapy and patient convenience driving the next decade of growth.